Presentation of 36 abstracts underscore the potential of Elekta Unity to advance precision radiation medicine
Comparison of CT-Guided and MR-Guided Adaptive Radiotherapy for Intramuscular Metastasis
Intramuscular tumors are not visible on CT scans but can be imaged on MR scans. This abstract describes data from a patient with an intramuscular tumor treated with MR-guided radiation therapy (MRgRT) using Elekta Unity. MR images were captured at the start of each treatment session and used to adapt the delivered dose to the size and shape of the tumor at the time of therapy. An algorithm was also developed to simulate the changes in daily doses that would have occurred using CT-guided radiation therapy (CTgRT). Results show that the use of CTgRT to treat intramuscular tumors can result in significant under-dosing and failure to treat the entire tumor. The authors conclude that MRgRT is ideal for treating tumors that are not visible on CT.
Real-Time Motion Tracking Based On Orthogonal Cine MRI for Abdominal Tumors On 1.5T MR-Linac
A key challenge in the use of radiation therapy to treat tumors within the abdomen is the movement of these tumors and nearby organs as the patient breathes. Real- time motion tracking (RMT) has the potential to adjust for breathing-related intra-abdominal motion and enable more precise delivery of radiation to the tumor while sparing surrounding healthy tissue and organs at risk of exposure. This abstract validates a motion tracking algorithm based on MR images captured with Elekta Unity. The algorithm was qualitatively and quantitatively validated on nine sets of abdominal MR images from eight patients with pancreatic or renal tumors and showed robust performance for real-time motion tracking, even in cases with implant-induced image artefacts or a suboptimal imaging plane.
Quantitative Relaxometry for Ultra-Hypofractionated MR-Guided Radiotherapy to the Prostate and DIL: A Feasibility Study
This study shows how T1 and T2 relaxation times (known as quantitative relaxometry) can be reliably acquired on Unity. Data was acquired in eight patients with prostate cancer while being treated with an integrated boost to the dominant intra-prostatic lesion (DIL) using ultra-hypofractionated radiotherapy on Unity. Results suggest that quantitative relaxometry may have clinical utility as an imaging biomarker to assess how tumors are responding to treatment, potentially enabling changes to the treatment plan that could improve patient outcomes.
To learn more about Elekta Unity, visit elekta.com/Unity.
Elekta Unity has CE mark and 510(k) clearance but is not available in all markets.
# # #
For further information, please contact:
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time
Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,400 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in
https://news.cision.com/elekta/r/data-from-14-leading-cancer-centers-presented-at-aapm-highlight-global-adoption-of-elekta-unity-mr-l,c3388327
https://mb.cision.com/Main/35/3388327/1447518.pdf
https://news.cision.com/elekta/i/elekta-unity,c2937862
(c) 2021 Cision. All rights reserved., source